Triglyceride-glucose index and the risk of heart failure: evidence from two large

2 cohorts and a Mendelian randomization analysis

- 3 Short Title: Triglyceride-glucose index and the risk of heart failure
- 4 Xintao Li, MD ^{1,2†}, Jeffrey Shi Kai Chan, MBChB ^{2†}, Bo Guan, MD ³, Shi Peng, MD,
- 5 PhD ¹, Xiaoyu Wu, MD ¹, Jiandong Zhou, PhD ^{2,5}, Jeremy Man Ho Hui ², Yan Hiu
- 6 Athena Lee ², Danish Iltaf Satti ², Shek Long Tsang MBBS ², Shouling Wu, MD, PhD
- ⁴, Songwen Chen, MD, PhD ^{1*}, Gary Tse, MD, PhD ^{2,6,7*}, Shaowen Liu, MD, PhD ^{1*}.
- 9 ¹ Department of Cardiology, Shanghai General Hospital, School of Medicine, Shanghai
- 10 Jiao Tong University, Shanghai, China
- ² Cardiovascular Analytics Group, Hong Kong United Kingdom China
- 12 collaboration

1

8

21

22

- ³ Geriatric Cardiology Department of the Second Medical Center and National Clinical
- Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
- ⁴ Department of Cardiology, Kailuan General Hospital, Tangshan 063000, China.
- ⁵ Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- 17 ⁶ Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, United Kingdom.
- ⁷ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease,
- 19 Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin
- 20 Medical University, Tianjin 300211, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23	These authors have contributed equally to this work and share first authorship
24	
25	Corresponding author:
26	Professor Shaowen Liu, MD, PhD, Department of Cardiology, Shanghai General
27	Hospital, School of Medicine, Shanghai Jiao Tong University, 200080 Shanghai, China
28	Email: shaowen.liu@hotmail.com
29	
30	Co-corresponding author:
31	Professor Gary Tse, MD, PhD, Kent and Medway Medical School, Canterbury, Kent,
32	CT2 7NT, United Kingdom. Email: garytse86@gmail.com
33	Dr. Songwen Chen, MD, PhD, Department of Cardiology, Shanghai General Hospital,
34	School of Medicine, Shanghai Jiao Tong University, 200080 Shanghai, China
35	Email: chensongwen@hotmail.com
36	
37	Total word count of the manuscript:
38	

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Abstract Background: The relationship between triglyceride-glucose (TyG) index, an emerging marker of insulin resistance, and the risk of incident heart failure (HF) was unclear. This study thus aimed to investigate this relationship. Methods: Subjects without prevalent cardiovascular diseases from the prospective Kailuan cohort (recruited during 2006-2007) and a retrospective cohort of family medicine patients from Hong Kong (recruited during 2000-2003) were followed up until December 31st, 2019 for the outcome of incident HF. Separate adjusted hazard ratios (aHRs) summarizing the relationship between TyG index and HF risk in the two cohorts were combined using a random-effect meta-analysis. Additionally, a twosample Mendelian randomization (MR) of published genome-wide association study data was performed to assess the causality of observed associations. **Results**: In total, 95,996 and 19,345 subjects from the Kailuan and Hong Kong cohorts were analyzed, respectively, with 2,726 cases (2.8%) of incident HF in the former and 1,709 (7.0%) in the latter. Subjects in the highest quartile of TyG index had the highest risk of incident HF in both cohorts (Kailuan: aHR 1.23 (95% confidence interval: 1.09-1.39), *P*_{Trend} < 0.001; Hong Kong: aHR 1.21 (1.04-1.40), *P*_{Trend} = 0.007; both compared with the lowest quartile). Meta-analysis showed similar results (highest versus lowest quartile: HR 1.22(1.11-1.34), P<0.0001). Findings from MR analysis, which included 47,309 cases and 930,014 controls, supported a causal relationship between higher TyG

- 61 index and increased risk of HF (odds ratio 1.27(1.15-1.40), *P*<0.001).
- 63 **Conclusion**: A higher TyG index is an independent and causal risk factor for incident
- 64 HF in the general population.

65

68

- 66 Keywords: Heart failure; Triglyceride-glucose index; Risk stratification; Mendelian
- 67 Randomization; Insulin resistance.

Clinical Perspective:

What is new?

69

70

79

84

- In 115,341 subjects from two large cohorts in China, an elevated triglyceride-
- 72 glucose (TyG) index was independently associated with an increased risk of
- 73 incident heart failure (HF).
- Two-sample Mendelian randomization analysis based on published genome-wide
- association studies found significant association between genetically determined
- 76 TyG index and the risk of HF.
- Together, these findings suggest that a higher TyG index is an independent and
- causal risk factor of incident HF in the general population.

What are the clinical implications?

- The TyG index may facilitate recognition of individuals at elevated risk of incident
- 81 HF and allow early preventive interventions.
- The demonstrated causal effect of TyG index on incident HF warrants further
- research to fully understand the underlying mechanisms.

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Introduction Heart failure (HF) is associated with significant morbidity and mortality, with contemporary five-year survival rates of less than 50%¹. The prevalence of HF has been estimated to be 1-2% in developed countries and is projected to double by 2060^{2, 3}. Given the enormous public health and socioeconomic burden caused by HF, it is critically important to identify individuals at high risk of HF and to implement preventive interventions as early as possible⁴. Recently, the role of metabolic disorders in the development of HF has been increasingly investigated⁵. Insulin resistance, a hallmark of type II diabetes mellitus and metabolic syndrome, has been observed to be associated with adverse cardiac remodeling and dysfunction⁶. Molecular studies have provided ample evidence for the etiological role of insulin resistance in the development of HF^{7, 8}. However, the gold standard method for measuring insulin sensitivity, the hyperinsulinaemic-euglycaemic clamp test, is time-consuming and invasive⁹, which has impeded its widespread use in clinical practice. The triglyceride-glucose (TyG) index, a simple, dimensionless marker derived from fasting blood triglyceride and glucose levels as measured in routine biochemical tests, has been proposed and validated as a surrogate marker of insulin resistance¹⁰. Previous studies have found a positive association between TyG index and the risk of various metabolic and atherosclerotic cardiovascular diseases^{11, 12}. However, few studies have

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

been conducted to investigate the association between TyG index and the risk of incident HF, and whether the association is causal remains undetermined. Mendelian randomization (MR) makes use of genetic variants as instrumental variables (IVs) to generate causal estimates of the long-term effects of risk factors on outcomes ¹³. MR analysis can overcome the limitations of residual confounding and reverse causation in conventional observational studies^{13, 14}. With the development of genomewide association studies (GWAS), MR is highly suited and has been used for investigating the causal association between TvG index and HF^{15, 16}. As such, the present study aimed to assess the association between the TyG index and the risk of incident HF, as well as using a two-sample MR study to determine whether such associations were causal in nature. Methods Study design and population Study subjects were identified from two Chinese studies, the Kailuan cohort in northern China and a territory-wide cohort in Hong Kong. The protocol for this study was in accordance with the guidelines of the Helsinki Declaration and this study was approved by the Ethics Committee at the Kailuan General Hospital and the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster.

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

The Kailuan Study is a prospective cohort that based on a community in the Tangshan City. Details of the study has been published elsewhere¹⁷. In brief, a total of 101,510 subjects (aged 18 – 98 years; 81,110 males) were enrolled in the Kailuan Study at baseline (2006-2007), and received an interview of standardized questionnaires and clinical examinations at 11 hospitals responsible for health care of the community. The subjects were then followed up with repeat questionnaires, clinical and laboratory examinations every two years. All subjects gave informed consent to their enrolment in this study. Subjects with prevalent cancer and cardiovascular diseases, including HF, atrial fibrillation (AF), myocardial infarction (MI), and ischemic stroke were excluded, as well as those with missing baseline levels of triglyceride (TG) or fasting blood glucose (FBG). Data for the Hong Kong cohort were extracted retrospectively from the Clinical Data Analysis and Reporting System (CDARS), an administrative electronic medical records database that records the basic demographics, diagnoses, selected procedures, medication prescriptions, and selected laboratory measurements of all patients that attended public healthcare institutions in Hong Kong which serve an estimated 90% of the population¹⁸. Diagnoses in CDARS were recorded using International Classification of Diseases, Ninth revision (ICD-9) codes regardless of the time of data entry, as ICD-10 has not been implemented in CDARS to date. The ICD-9 codes used for identifying comorbid conditions and the outcome (HF) were summarized in Table S1. CDARS has been extensively used in prior studies and has been shown to have good diagnostic

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

coding accuracy^{19, 20}. As only retrospective, deidentified data were used, the requirement for individual patient consent has been waived. For this study, adult patients (18 years old or above) attending a family medicine clinic in Hong Kong during the years 2000-2003 with at least one set of paired FBG and fasting TG levels at baseline were included. Patients with a history of ischemic heart disease, stroke, HF, AF, or cancer were excluded, as well as those who were pregnant at the time of inclusion, and those with missing baseline low-density lipoprotein cholesterol (LDL-C), highdensity lipoprotein cholesterol (HDL-C), and total cholesterol levels. Data collection and definitions The data collected and definitions used in this study were detailed in **Supplementary** Methods^{17,21,22}. The TyG index was calculated as ln [fasting TG (mg/dl)×FBG (mg/dl) $/2]^{23}$. *Outcomes and follow-up* In the Kailuan cohort, all subjects were followed from the baseline examination until the date of onset of HF, date of death, or end of follow-up (December 31st, 2019), whichever came first. HF was diagnosed by experienced cardiologists in accordance with the guidelines of the European Society of Cardiology²⁴. Incident HF cases were derived from the Municipal Social Insurance Institutions, hospital discharge register, and death certificates.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

In the Hong Kong cohort, all patients were followed up from inclusion until the first recorded diagnosis of HF, death, or the end of follow-up (December 31st, 2019), whichever came first. HF was identified using ICD-9 codes as summarized in Table S1. Two-sample MR analysis Mendelian randomization is built upon three main assumptions²⁵. First, singlenucleotide polymorphisms (SNPs) selected as instrumental variables should be robustly associated with the risk factor. Second, no association should exist between genetic variants and confounders. Third, genetic variants should affect outcome only through the risk factor. TyG index-associated variants that reached genome-wide significance ($P < 5 \times 10^{-8}$) were retrieved from a previous GWAS¹⁶. In brief, the identified GWAS included 273,368 subjects from the United Kingdom Biobank, who were aged 40-69 and free from diabetes mellitus and lipid metabolism disorders¹⁶. These SNPs were further pruned by linkage disequilibrium with $R^2 < 0.01$ and those that were significantly associated with TG or glucose were also excluded. In total, 192 IVs were selected for TyG index initially. Summary statistics data for the associations of TyG indexassociated SNPs with HF were extracted from the published GWAS performed by the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium on 47,309 cases and 930,014 controls of European ancestry²⁶. HF cases from 26 cohorts of the HERMES Consortium were identified based on the clinical diagnosis of HF of

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

any etiology with no specific criteria for left ventricular ejection fraction. Details of subject selection were published elsewhere²⁶. Statistical analysis Continuous variables were presented as mean \pm standard deviation (SD) or median with interquartile range (IQR) depending on their distribution. Categorical variables were presented as frequencies and percentages. Kaplan-Meier curves were used to visualize the cumulative incidence of HF across quartiles of the TyG index. The association between baseline TyG index and the risk of incident HF was analyzed using the Cox proportional hazards model, with hazard ratios (HR) with 95% confidence intervals (CI) as the summary statistics. The Cox regression was performed with a staged approach, as detailed in Supplementary Methods. The association between the risks of HF and the observed spectrum of TyG index was also modelled and visualized using fractional polynomial curves with full multivariable adjustments. Furthermore, competing risk regression using the Fine and Gray subdistribution model was performed to address the potentially confounding issue of competing risk, with death from any cause as the competing event. Sub-hazard ratios (SHR) with 95% CI were used as the summary statistics. Sensitivity analyses were conducted by excluding subjects with less than two-year follow-up time, and, separately, those with medications at baseline.

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

A priori subgroup analyses were performed for age (<65 vs ≥65), gender (male vs female), diabetes (yes vs no), hypertension (yes vs no), dyslipidemia (yes vs no) for both cohorts, and, for the Kailuan cohort, for obesity (yes vs no), and hs-CRP level (<1 mg/dl vs > 1 mg/dl). To combine the results from the two cohorts, we extracted hazard ratios from the fully adjusted model and performed a meta-analysis using the inverse variance method with random effects to estimate the association between TyG index, both as categorical and continuous variables, and the risk of incident HF. In the MR analysis, the summary exposure and outcome data were first harmonized, and SNPs significantly associated with incident HF were excluded. Causal effects of TyG index on HF were estimated by the inverse-variance weighted (IVW) method. Weighted median, MR-Egger, and pleiotropy residual sum and outlier (MR-PRESSO) methods were used for supplementary analyses. Directional pleiotropy was assessed by MR-Egger intercepts and heterogeneity among genetic variants was evaluated by Cochran's Q test. To test the validity of causal effects estimates, multivariable MR (MVMR) using the IVW method was conducted to further investigate the direct causal effect of TyG index on HF after adjusting for confounders including BMI²⁷, SBP²⁸, DBP²⁸, LDL-c²⁹, and HDL-c²⁹. An additional sensitivity analysis was performed by excluding any SNP

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

significantly associated with those confounders. All statistical analyses for the Kailuan and Hong Kong cohorts were conducted using SAS version 9.4 (SAS Institute, Inc., Cary, NC), Stata 16.1 software (StataCorp, College Station, TX), and/or RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK). The MR analyses were performed by the TwoSampleMR, MR-PRESSO and MVMR packages with R version 4.0.2. All p values were two-sided, with p < 0.05considered statistically significant. **Results** Of the 101,510 subjects who took part in the Kailuan study, 95,996 subjects were analyzed after applying the exclusion criteria (Figure S1). For the Hong Kong cohort, 24,338 patients were identified for inclusion, and 19,345 patients were analyzed after applying the exclusion criteria (Figure S2). Table 1 and Table 2 shows the baseline characteristics of subjects according to the baseline TyG index quartiles of two cohorts. In the Kailuan cohort, there were 2,726 cases (2.8%) of incident HF over a mean followup of 12.3±2.2 years, with an overall incidence rate of 2.3 (95% CI 2.2-2.4) cases per 1000 person years. In the Hong Kong cohort, there were 1,709 cases (7.0%) of incident HF over a mean follow-up of 16.2±4.3 years, with an overall incidence rate of 5.5 (95% CI 5.3-5.8) cases per 1000 person years. Over the study duration, 10,825 subjects (11.3%) in the Kailuan cohort died (9,985 (10.1%) without developing HF), while 6,372

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

patients (32.9%) in the Hong Kong cohort died (4,996 (25.8%) without developing HF). Associations between the TyG index and the risk of incident HF Table 3 and Table 4 show the associations between the TyG index, assessed both as a categorial and continuous variable, with the respective risks of incident HF in the Kailuan and Hong Kong cohorts. The cumulative incidence of incident HF for the Kailuan and the Hong Kong cohort is shown in Figures 1A and 1B, respectively. After fully adjusting for potential confounders, patients in the highest quartile of the TyG index had significantly higher risks of incident HF than those in the lowest quartile in both the Kailuan (HR 1.23 (95% CI 1.09-1.39), P < 0.001) and Hong Kong (HR 1.21 (95% CI 1.04-1.40), P = 0.007) cohorts. Similarly, every unit increment in the TyG index was associated with a 17% and a 13% increase in the risk of HF in the Kailuan (HR 1.17 (95% CI 1.10-1.24), P < 0.001) and Hong Kong (HR 1.13 (95% CI 1.05-1.22), P<0.001) cohorts, respectively. Fractional polynomial curves with full multivariable adjustment (Figure S3) showed a possible threshold effect in the prognostic value of the TyG index, with a lower TyG index showing no significant association with the risk of incident HF, and a higher TyG index showing a grossly linear relationship with the said risk. This was consistent with the multivariable Cox regression analysis as shown in Tables 3 and 4 with TyG index analyzed as quartiles. Competing risk regression using the Fine and Gray sub-distribution model with death from any cause as the competing event also showed positive associations between a higher TyG index and a

high risk of incident HF (Tables 3 and 4). Sensitivity analyses produced consistent and

similar results (Tables 3 and 4).

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

Results of subgroup analyses are shown in Figure 2A and Figure 2B for the Kailuan and Hong Kong cohorts, respectively. Generally, the TyG index, analyzed as a continuous variable, was positively associated with the risk of HF across various subgroups. There was significant interaction between gender and the TyG index in the Kailuan cohort (P for interaction = 0.02), but not in the Hong Kong cohort (P for interaction = 0.11). The association between TyG index and the risk of incident HF was more prominent in female subjects than in male subjects in both cohorts [HR 1.21 (95%)] CI 1.02 -1.47) for female vs. 1.15 (95% CI 1.08 - 1.23) for male in the Kailuan cohort, and 1.22 (95% CI 1.10 -1.64) vs. 1.05 (95% CI 0.94 - 1.17) in the Hong Kong cohort]. A random-effect meta-analysis combining the results from the two cohorts showed that the risk of incident HF of subjects in the highest quartile of the TyG index was 22% higher (95% CI 11% - 34%, P<0.0001; **Figure 3A**) than those in the lowest quartile, with every unit increment of the TyG index being associated with a 15% increase in the risk of incident HF (95% CI 10% - 21%, P<0.00001; Figure 3B). Similarly, subjects in the highest quartile of the TyG index had a 25% (95% CI 13% - 37%) increase in the sub-hazard of incident HF.

Two-Sample MR analysis

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

The associations between genetically determined TyG index and the risk of incident HF as estimated by two-sample MR are presented in Figure 4. Analysis using the IVW method demonstrated that genetic predisposition to increased TyG index was significantly associated with an increased risk of incident HF (OR 1.27, 95% CI 1.15 -1.40, P<0.001). The Cochran's Q statistic indicated significant heterogeneity across SNPs, while no indication of directional pleiotropy was found by MR-Egger intercept (Table S3). The association remained consistent when using complementary methods for analysis, including weighted median, MR-Egger and MRPRESSO (Figure 4). To verify the causal effect of TyG index on HF, we performed multivariable MR analysis by adjusting for HF risk factors, including BMI, blood pressure, and lipids. The association remained stable after adjusting for single risk factors (Table S4) and in a fully adjusted model (OR 1.20, 95% CI 1.02-1.41, *P*=0.03; **Figure 4**). Furthermore, results of the sensitivity analysis, in which 32 SNPs with potential pleiotropy were excluded, confirmed the positive association between genetically determined TyG index and HF risk (OR 1.19, 95% CI 1.05 - 1.35, P=0.01). **Discussion** Utilizing observational data from two large Chinese cohorts and a two-sample MR analysis based on a public GWAS dataset, this study demonstrated that a high TyG index was an independent and causal risk factor for incident HF in the general population.

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Previous studies have found independent associations between TyG index and risks of atherosclerotic cardiovascular diseases, including myocardial infarction and ischemic stroke^{23, 30}. In a recent analysis of data from the Atherosclerosis Risk in Communities (ARIC) study, Huang et al. also reported an association between higher TyG index and higher risk of incident HF in an American population, with every standard deviation's increase in TyG index (corresponding to a TyG index of 0.6) associated with a 15% increase in risk³¹. Our study confirmed these findings in two larger cohorts from distinct geographical regions in China. Unlike the ARIC study which was restricted to subjects between the ages of 45-64 years old, our study included adult patients across the full age range. As such, our study more closely reflects real-life practice, and our findings are thus more directly generalizable. Importantly, utilizing MR of GWAS data, we demonstrated that the association between TyG and HF was causal by nature. Although the exact underlying mechanism for the association between TyG index and HF remains to be confirmed by further molecular studies, the well-established relationship between TyG index and insulin resistance suggests that insulin resistance may at least be an important driver of such association¹⁰. This was further reinforced by the results from the Kailuan cohort showing that the association between TyG index and HF was independent of chronic inflammation, as well as previous studies observing associations between insulin resistance and higher risks of incident HF independent of myocardial ischaemia³²⁻³⁴. Insulin resistance may

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

lead to excessive circulating free fatty acids and triglycerides, which induces cardiac lipotoxicity by generating toxic lipid intermediates, and decreases cardiac efficiency by increasing fatty acid oxidation^{35, 36}. Insulin resistance is also associated with disturbances of the systemic metabolic and inflammatory milieu, including increased concentrations of proinflammatory cytokines, adipokines, and catecholamines, which may trigger low-grade inflammation and chronic hypercatecholaminemia that result in detrimental effects on cardiac function³⁷. Furthermore, insulin resistance is involved in the maladaptive activation of the renin-angiotensin-aldosterone system, with chronic hyperinsulinaemia inducing increased release of angiotensinogen from adipose tissue and upregulation of angiotensin II receptor expression, eventually resulting in adverse cardiac remodeling and dysfunction³⁸. Nonetheless, the mechanisms between insulin resistance and HF are incompletely understood to date, and remain an important area of further research. Another major finding of the present study is that the association between TyG index and the risk of HF was stronger in females than in males. Between-gender differences are common in cardiovascular medicine. Previous studies have shown that women with disorders of glucose metabolism have a greater risk of coronary heart disease than men^{30, 39}. HF caused by obesity, diabetes, or metabolic syndrome was also found to be more common in women⁴⁰. These suggest that between-gender differences in molecular mechanisms, particularly those in hormonal axes, may not only influence glucose and lipid metabolism, but also energy metabolism in the heart and, thereby, cardiac function.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

Females are known to be less likely than males to develop insulin resistance⁴¹ but are at higher risk of diabetic cardiomyopathy⁴², implying that females may be more susceptible to cardiac damage induced by insulin resistance. Gender differences in nitric oxide synthase (NOS) activity and signaling, which are critical in metabolic regulation and in modulating responses to insulin resistance, are thought to be central to these observations⁴³. The higher baseline levels of NOS in females predisposes to higher levels of uncoupled NOS on exposure to oxidative stress, which exacerbates the effects of insulin resistance, such as myocardial fibrosis and hypertrophy⁴³. Additionally, considering that the mean age of subjects in this study implied that the female subjects were mostly postmenopausal, the postmenopausal decline in the protective effects of estrogen may contribute to gender differences in the susceptibility to insulin resistance-induced cardiac damage⁴⁰. Notwithstanding the existing evidence as discussed above, further studies exploring the gender differences in susceptibility to insulin resistance-induced cardiac damage should provide important insights and better understanding of diabetic cardiomyopathy. Having derived consistent findings from two geographically distinct regions in China, our results suggest that the TyG index, as a surrogate marker of insulin resistance, may be widely applicable and prognostically useful regardless of geographical region and ethnicity. As subjects with prevalent major cardiovascular diseases were excluded from the present study, the analyzed cohorts had relatively low cardiovascular risks. Our results supported the TyG index as a potentially viable and effective tool for

cardiovascular risk stratification in the general population. Of note, insulin resistance in many previous studies was measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) which requires measurements of fasting insulin and glucose^{32, 33}. However, measuring insulin levels is expensive, and the HOMA-IR has been mostly confined to research uses with low clinical utilization. In contrast, the TyG index is simple to measure, has been validated against the euglycemic-hyperinsulinemic clamp test which is considered the gold standard for measuring insulin resistance¹⁰, and may outperform the HOMA-IR in identifying insulin resistance⁴⁴. It has also been shown to be excellent at detecting insulin resistance in non-diabetic patients⁴⁵, which is important as insulin resistance and its associated cardiovascular damage precedes overt type II diabetes mellitus⁴⁶. The TyG index may therefore facilitate recognition of patients at elevated risk of incident HF, for which efficacious measures for primary prevention exist⁴.

Strengths and limitations

The strengths of our study included the large sample size, long follow-up time, and having demonstrated reproducible results across two independent observational cohorts and MR analysis. Our findings were further strengthened by multiple subgroup and sensitivity analyses yielding largely consistent results. To the best of the authors' knowledge, this was one of the first studies demonstrating causality between higher TyG index and higher risk of incident HF. Nonetheless, some limitations must be noted. First, we were unable to compare the predictive power of different methods for

assessing insulin resistance in our observational study, since fasting insulin levels were unavailable for most subjects. Second, inherent to all observational studies, there may be residual or unmeasured confounders that we were not able to address. Nonetheless, we have included multiple important risk factors for incident HF in the multivariable regression models, and the numerous sensitivity analyses yielded consistent results which reinforced the validity of our findings. Third, the MR analysis was restricted to patients of European descent to reduce bias from population stratification, which may limit extrapolation of our MR results to other populations. Nevertheless, given that associations between TyG index and the risk of incident HF observed in a recent report in an American cohort (the ARIC study) were comparable to our findings as observed in Chinese cohorts, the causality established by our MR analysis is likely true in Chinese patients as well. Fourth, no information was available about the subtype of incident HF. Given the different metabolic mechanisms contributing to the pathogenesis of different types of HF⁴⁷, further research in this regard is warranted. Fifth, diagnoses of the Hong Kong cohort were identified using ICD-9 codes and could not be individually adjudicated due to the retrospective, deidentified nature of the database, as well as the large sample size. Regardless, all diagnostic codes were entered by treating clinicians, who were completely independent of the authors. CDARS has also been shown to have good coding accuracy, specifically for cardiovascular outcomes²⁰.

Conclusion

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

As observed from two large, geographically distinct Chinese cohorts, a higher TyG

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

index was independently associated with higher risk of incident HF. MR analysis demonstrated that the association was likely causal in nature. Further studies are warranted to confirm our findings and fully elucidate the underlying biological mechanisms. Acknowledgements The authors appreciate all the subjects involved in this study, their families, and the members of the survey team from the Kailuan community. **Author contributions** Xintao Li and Jeffrey Shi Kai Chan designed this study, conducted the main analysis, visualized the results, and wrote the first draft of the manuscript. Bo Guan, Shi Peng, Xiaoyu Wu, Yan Hiu Athena Lee, Jeremy Man Ho Hui, Danish Iltaf Satti, Shek Long Tsang, Shouling Wu, Jiandong Zhou, Songwen Chen, Gary Tse, and Shaowen Liu reviewed and edited the article. All authors contributed to the article significantly and approved the submitted version. **Funding Sources** This work was supported by the National Natural Science Foundation of China (Grant No. 81970273). **Disclosures:**

458 None.

References

459

- 460 1. Ziaeian B and Fonarow GC. Epidemiology and aetiology of heart failure. Nat
- 461 Rev Cardiol. 2016;13:368-78.
- 462 2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri
- 463 H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG,
- 464 Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak
- 465 M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C,
- 466 Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F and Kathrine Skibelund
- 467 A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
- 468 failure. Eur Heart J. 2021;42:3599-3726.
- 469 3. de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha
- 470 MJ, Brouwers FP, Cushman M, Lima JAC, Bahrami H, van der Harst P, Wang TJ,
- 471 Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS,
- 472 Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL, Jr.,
- Shah SJ, Levy D, Herrington DM, Larson MG, van Gilst WH, Gottdiener JS, Bertoni
- 474 AG and Ho JE. Association of Cardiovascular Biomarkers With Incident Heart
- 475 Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiol. 2018;3:215-
- 476 224.
- 477 4. Greene SJ and Butler J. Primary Prevention of Heart Failure in Patients With
- 478 Type 2 Diabetes Mellitus. *Circulation*. 2019;139:152-154.
- 479 5. Ho KL, Karwi QG, Connolly D, Pherwani S, Ketema EB, Ussher JR and
- Lopaschuk GD. Metabolic, structural and biochemical changes in diabetes and the

- development of heart failure. *Diabetologia*. 2022;65:411-423.
- 482 6. Kishi S, Gidding SS, Reis JP, Colangelo LA, Venkatesh BA, Armstrong AC,
- 483 Isogawa A, Lewis CE, Wu C, Jacobs DR, Jr., Liu K and Lima JA. Association of Insulin
- 484 Resistance and Glycemic Metabolic Abnormalities With LV Structure and Function
- in Middle Age: The CARDIA Study. *JACC Cardiovasc Imaging*. 2017;10:105-114.
- 486 7. Riehle C and Abel ED. Insulin Signaling and Heart Failure. Circ Res.
- 487 2016;118:1151-69.
- 488 8. Velez M, Kohli S and Sabbah HN. Animal models of insulin resistance and
- 489 heart failure. *Heart Fail Rev.* 2014;19:1-13.
- 490 9. Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J and Bastard
- 491 JP. How can we measure insulin sensitivity/resistance? Diabetes Metab.
- 492 2011;37:179-88.
- 493 10. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-
- 494 Abundis E, Ramos-Zavala MG, Hernández-González SO, Jacques-Camarena O
- 495 and Rodríguez-Morán M. The product of triglycerides and glucose, a simple
- 496 measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic
- 497 clamp. *J Clin Endocrinol Metab*. 2010;95:3347-51.
- 498 11. Ding X, Wang X, Wu J, Zhang M and Cui M. Triglyceride-glucose index and
- the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort
- studies. Cardiovasc Diabetol. 2021;20:76.
- 12. Zou S, Yang C, Shen R, Wei X, Gong J, Pan Y, Lv Y and Xu Y. Association
- Between the Triglyceride-Glucose Index and the Incidence of Diabetes in People

- With Different Phenotypes of Obesity: A Retrospective Study. Front Endocrinol
- 504 *(Lausanne)*. 2021;12:784616.
- 505 13. Smith GD and Ebrahim S. 'Mendelian randomization': can genetic
- 506 epidemiology contribute to understanding environmental determinants of
- 507 disease? Int J Epidemiol. 2003;32:1-22.
- 508 14. Larsson SC, Burgess S and Michaelsson K. Association of Genetic Variants
- Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial
- 510 Infarction. *Jama*. 2017;318:371-380.
- 15. Li X, Peng S, Guan B, Chen S, Zhou G, Wei Y, Gong C, Xu J, Lu X, Zhang X and
- 512 Liu S. Genetically Determined Inflammatory Biomarkers and the Risk of Heart
- Failure: A Mendelian Randomization Study. *Front Cardiovasc Med.* 2021;8:734400.
- 16. Si S, Li J, Li Y, Li W, Chen X, Yuan T, Liu C, Li H, Hou L, Wang B and Xue F.
- Causal Effect of the Triglyceride-Glucose Index and the Joint Exposure of Higher
- 516 Glucose and Triglyceride With Extensive Cardio-Cerebrovascular Metabolic
- 517 Outcomes in the UK Biobank: A Mendelian Randomization Study. Front
- 518 *Cardiovasc Med.* 2020;7:583473.
- 17. Wu S, Huang Z, Yang X, Zhou Y, Wang A, Chen L, Zhao H, Ruan C, Wu Y, Xin
- A, Li K, Jin C and Cai J. Prevalence of ideal cardiovascular health and its relationship
- with the 4-year cardiovascular events in a northern Chinese industrial city. Circ
- 522 Cardiovasc Qual Outcomes. 2012;5:487-93.
- 18. Kong X, Yang Y, Gao J, Guan J, Liu Y, Wang R, Xing B, Li Y and Ma W. Overview
- of the health care system in Hong Kong and its referential significance to mainland

- 525 China. *J Chin Med Assoc*. 2015;78:569-73.
- 19. Chan JSK, Satti DI, Lee YHA, Hui JMH, Lee TTL, Chou OHI, Wai AKC, Ciobanu
- A, Liu Y, Liu T, Roever L, Biondi-Zoccai G, Zhang Q, Cheung BMY, Zhou J and Tse
- 528 G. High visit-to-visit cholesterol variability predicts heart failure and adverse
- 529 cardiovascular events: a population-based cohort study. Eur J Prev Cardiol. 2022.
- 530 20. Wong AY, Root A, Douglas IJ, Chui CS, Chan EW, Ghebremichael-
- Weldeselassie Y, Siu CW, Smeeth L and Wong IC. Cardiovascular outcomes
- associated with use of clarithromycin: population based study. *Bmj*
- 533 2016;352:h6926.
- 534 21. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M
- and Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice
- 536 guideline for the evaluation and management of CKD. Am J Kidney Dis.
- 537 2014;63:713-35.
- 538 22. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC,
- Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V,
- 540 Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby
- R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W,
- Ballew SH, Couture SJ, Powe NR and Levey AS. New Creatinine- and Cystatin C-
- Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385:1737-
- 544 1749.
- 545 23. Wang A, Wang G, Liu Q, Zuo Y, Chen S, Tao B, Tian X, Wang P, Meng X, Wu
- 546 S, Wang Y and Wang Y. Triglyceride-glucose index and the risk of stroke and its

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

subtypes in the general population: an 11-year follow-up. Cardiovasc Diabetol. 2021;20:46. 24. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L and Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40. 25. Burgess S, Scott RA, Timpson NJ, Davey Smith G and Thompson SG. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30:543-52. 26. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman & K, Wilk JB, Morley MP, Chaffin MD, Helgadottir A, Verweij N, Dehghan A, Almgren P, Andersson C, Aragam KG, Ärnlöv J, Backman JD, Biggs ML, Bloom HL, Brandimarto J, Brown MR, Buckbinder L, Carey DJ, Chasman DI, Chen X, Chen X, Chung J, Chutkow W, Cook JP, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Dunn ME, Engström G, Esko T, Felix SB, Finan C, Ford I, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gutmann R, Haggerty CM, van der Harst P, Hyde CL, Ingelsson E, Jukema JW, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Margulies KB, März W, Melander O, Mordi IR, Morgan T, Morris AD, Morris AP, Morrison AC, Nagle MW,

Nelson CP, Niessner A, Niiranen T, O'Donoghue ML, Owens AT, Palmer CNA, Parry 569 HM, Perola M, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, 570 Rotter Jl, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, 571 Stender S, Stott DJ, Svensson P, Tammesoo ML, Taylor KD, Teder-Laving M, 572 Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tyl B, 573 574 Uitterlinden AG, Veluchamy A, Völker U, Voors AA, Wang X, Wareham NJ, Waterworth D, Weeke PE, Weiss R, Wiggins KL, Xing H, Yerges-Armstrong LM, Yu 575 B, Zannad F, Zhao JH, Hemingway H, Samani NJ, McMurray JJV, Yang J, Visscher 576 PM, Newton-Cheh C, Malarstig A, Holm H, Lubitz SA, Sattar N, Holmes MV, 577 Cappola TP, Asselbergs FW, Hingorani AD, Kuchenbaecker K, Ellinor PT, Lang CC, 578 Stefansson K, Smith JG, Vasan RS, Swerdlow DI and Lumbers RT. Genome-wide 579 580 association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature communications. 2020;11:163. 581 27. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam 582 S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, 583 584 Gustafsson S, Kutalik Z, Luan J, Mägi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman 585 Å K, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton 586 JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa 587 588 MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM, Medina-Gomez C, Medland SE, Nalls MA, 589 Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stančákov 590

á A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, 591 592 van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, 593 Albrecht E, Ärnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Blüher M, Böhringer S, Bonnycastle LL, Böttcher 594 595 Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen YI, Clarke R, Daw EW, de Craen 596 AJM, Delgado G, Dimitriou M, Doney ASF, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall 597 AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Gräßler J, Grönberg 598 H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, 599 Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, 600 Hottenga JJ, James AL, Jeff JM, Johansson Å, Jolley J, Juliusdottir T, Kinnunen L, 601 Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, 602 Lichtner P, Lind L, Lindström J, Lo KS, Lobbens S, Lorbeer R, Lu Y, Mach F, 603 Magnusson PKE, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, 604 Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Müller G, 605 606 Müller-Nurasyid M, Musk AW, Nagaraja R, Nöthen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, 607 608 Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Smith AV, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundström 609 J, Swertz MA, Swift AJ, Syvänen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, 610 Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, 611 Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, 612

613 Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gådin JR, Gharavi AG, 614 Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, 615 Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, 616 Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, 617 618 Perry JRB, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, van 't Hooft FM, Vinkhuyzen AAE, Westra HJ, Zheng W, 619 Zondervan KT, Heath AC, Arveiler D, Bakker SJL, Beilby J, Bergman RN, Blangero 620 J. Bovet P. Campbell H. Caulfield MJ. Cesana G. Chakravarti A. Chasman DI. Chines 621 622 PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini 623 624 E, Ferrières J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, 625 Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, 626 Hovingh GK, Humphries SE, Hunt SC, Hyppönen E, Illig T, Jacobs KB, Jarvelin MR, 627 628 Jöckel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJP, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, 629 630 Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Marchand LL, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise TC, McKenzie CA, 631 McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, 632 Oldehinkel AJ, Ong KK, Madden PAF, Pasterkamp G, Peden JF, Peters A, Postma 633 DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker 634

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PEH, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tönjes A, Trégouët DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Völker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PIW, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, März W, Melbye M, Metspalu A, Moebus S, Munroe PB, Niølstad I, Oostra BA, Palmer CNA, Pedersen NL, Perola M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJF and Speliotes EK. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197-206. 28. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, Ng FL, Evangelou M, Witkowska K,

Tzanis E, Hellwege JN, Giri A, Velez Edwards DR, Sun YV, Cho K, Gaziano JM, 657 Wilson PWF, Tsao PS, Kovesdy CP, Esko T, Mägi R, Milani L, Almgren P, Boutin T, 658 Debette S, Ding J, Giulianini F, Holliday EG, Jackson AU, Li-Gao R, Lin WY, Luan J, 659 Mangino M, Oldmeadow C, Prins BP, Qian Y, Sargurupremraj M, Shah N, 660 Surendran P, Thériault S, Verweij N, Willems SM, Zhao JH, Amouyel P, Connell J, 661 662 de Mutsert R, Doney ASF, Farrall M, Menni C, Morris AD, Noordam R, Paré G, Poulter NR, Shields DC, Stanton A, Thom S, Abecasis G, Amin N, Arking DE, Ayers 663 KL, Barbieri CM, Batini C, Bis JC, Blake T, Bochud M, Boehnke M, Boerwinkle E, 664 Boomsma DI, Bottinger EP, Braund PS, Brumat M, Campbell A, Campbell H, 665 Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M, Collins F, Cordell HJ, 666 Davies G, de Borst MH, de Geus EJ, Deary IJ, Deelen J, Del Greco MF, Demirkale 667 668 CY, Dörr M, Ehret GB, Elosua R, Enroth S, Erzurumluoglu AM, Ferreira T, Frånberg M, Franco OH, Gandin I, Gasparini P, Giedraitis V, Gieger C, Girotto G, Goel A, Gow 669 AJ, Gudnason V, Guo X, Gyllensten U, Hamsten A, Harris TB, Harris SE, Hartman 670 CA, Havulinna AS, Hicks AA, Hofer E, Hofman A, Hottenga JJ, Huffman JE, Hwang 671 672 SJ, Ingelsson E, James A, Jansen R, Jarvelin MR, Joehanes R, Johansson Å, Johnson AD, Joshi PK, Jousilahti P, Jukema JW, Jula A, Kähönen M, Kathiresan S, Keavney 673 674 BD, Khaw KT, Knekt P, Knight J, Kolcic I, Kooner JS, Koskinen S, Kristiansson K, Kutalik Z, Laan M, Larson M, Launer LJ, Lehne B, Lehtimäki T, Liewald DCM, Lin L, 675 Lind L, Lindgren CM, Liu Y, Loos RJF, Lopez LM, Lu Y, Lyytikäinen LP, Mahajan A, 676 Mamasoula C, Marrugat J, Marten J, Milaneschi Y, Morgan A, Morris AP, Morrison 677 AC, Munson PJ, Nalls MA, Nandakumar P, Nelson CP, Niiranen T, Nolte IM, Nutile 678

679 T, Oldehinkel AJ, Oostra BA, O'Reilly PF, Org E, Padmanabhan S, Palmas W, Palotie A, Pattie A, Penninx B, Perola M, Peters A, Polasek O, Pramstaller PP, Nguyen QT, 680 681 Raitakari OT, Ren M, Rettig R, Rice K, Ridker PM, Ried JS, Riese H, Ripatti S, Robino A, Rose LM, Rotter JI, Rudan I, Ruggiero D, Saba Y, Sala CF, Salomaa V, Samani NJ, 682 Sarin AP, Schmidt R, Schmidt H, Shrine N, Siscovick D, Smith AV, Snieder H, Sõber 683 684 S, Sorice R, Starr JM, Stott DJ, Strachan DP, Strawbridge RJ, Sundström J, Swertz MA, Taylor KD, Teumer A, Tobin MD, Tomaszewski M, Toniolo D, Traglia M, 685 Trompet S, Tuomilehto J, Tzourio C, Uitterlinden AG, Vaez A, van der Most PJ, van 686 Duijn CM, Vergnaud AC, Verwoert GC, Vitart V, Völker U, Vollenweider P, Vuckovic 687 D, Watkins H, Wild SH, Willemsen G, Wilson JF, Wright AF, Yao J, Zemunik T, Zhang 688 W, Attia JR, Butterworth AS, Chasman DI, Conen D, Cucca F, Danesh J, Hayward C, 689 690 Howson JMM, Laakso M, Lakatta EG, Langenberg C, Melander O, Mook-Kanamori DO, Palmer CNA, Risch L, Scott RA, Scott RJ, Sever P, Spector TD, van der Harst P, 691 Wareham NJ, Zeggini E, Levy D, Munroe PB, Newton-Cheh C, Brown MJ, Metspalu 692 A, Hung AM, O'Donnell CJ, Edwards TL, Psaty BM, Tzoulaki I, Barnes MR, Wain LV, 693 694 Elliott P and Caulfield MJ. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412-1425. 695 696 29. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, 697 698 Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkilä K, 699 Hyppönen E, Isaacs A, Jackson AU, Johansson Å, Johnson T, Kaakinen M, Kettunen 700

J, Kleber ME, Li X, Luan J, Lyytikäinen LP, Magnusson PKE, Mangino M, Mihailov E, 701 702 Montasser ME, Müller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, 703 Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik 704 EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, 705 706 Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney ASF, Döring A, Elliott P, Epstein SE, Ingi Eyjolfsson G, Gigante 707 B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, 708 Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu 709 710 P, Kastelein JJP, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lindström J, Loos RJF, Mach F, McArdle WL, Meisinger C, 711 712 Mitchell BD, Müller G, Nagaraja R, Narisu N, Nieminen TVM, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly 713 714 MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stančáková A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van 715 716 Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, 717 718 Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YI, Collins FS, Cooper 719 RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci L, Freimer 720 NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris TB, 721 722 Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE,

723 Hunt SC, Hveem K, Iribarren C, Järvelin MR, Jula A, Kähönen M, Kaprio J, Kesäniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, 724 Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, März W, McCarthy MI, 725 McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, 726 Njølstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous 727 728 T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PEH, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo 729 BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin 730 L, Wareham NJ, Whitfield JB, Wolffenbuttel BHR, Ordovas JM, Boerwinkle E, 731 732 Palmer CNA, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke 733 734 KL, Ingelsson E and Abecasis GR. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274-1283. 735 30. Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S and Wang A. Triglyceride-glucose 736 index is associated with the risk of myocardial infarction: an 11-year prospective 737 738 study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20:19. 31. Huang R, Lin Y, Ye X, Zhong X, Xie P, Li M, Zhuang X and Liao X. Triglyceride-739 740 glucose index in the development of heart failure and left ventricular dysfunction: analysis of the ARIC study. Eur J Prev Cardiol. 2022. 741 32. Banerjee D, Biggs ML, Mercer L, Mukamal K, Kaplan R, Barzilay J, Kuller L, Kizer 742

Insulin resistance and risk of incident heart failure: Cardiovascular Health Study.

JR, Djousse L, Tracy R, Zieman S, Lloyd-Jones D, Siscovick D and Carnethon M.

743

744

- 745 *Circ Heart Fail.* 2013;6:364-70.
- 33. Vardeny O, Gupta DK, Claggett B, Burke S, Shah A, Loehr L, Rasmussen-Torvik
- L, Selvin E, Chang PP, Aguilar D and Solomon SD. Insulin resistance and incident
- heart failure the ARIC study (Atherosclerosis Risk in Communities). *JACC Heart Fail*.
- 749 2013;1:531-6.
- 750 34. Wamil M, Coleman RL, Adler Al, McMurray JJV and Holman RR. Increased Risk
- of Incident Heart Failure and Death Is Associated With Insulin Resistance in People
- With Newly Diagnosed Type 2 Diabetes: UKPDS 89. Diabetes Care. 2021;44:1877-
- 753 1884.
- 35. Kolwicz SC, Jr., Purohit S and Tian R. Cardiac metabolism and its interactions
- with contraction, growth, and survival of cardiomyocytes. *Circ Res.* 2013;113:603-
- 756 16.
- 757 36. Yazıcı D and Sezer H. Insulin Resistance, Obesity and Lipotoxicity. Adv Exp
- 758 *Med Biol.* 2017;960:277-304.
- 759 37. Nishida K and Otsu K. Inflammation and metabolic cardiomyopathy.
- 760 *Cardiovasc Res.* 2017;113:389-398.
- 761 38. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M,
- Waagstein F and Holmäng A. Hyperinsulinemia: effect on cardiac mass/function,
- angiotensin II receptor expression, and insulin signaling pathways. *Am J Physiol*
- 764 *Heart Circ Physiol.* 2006;291:H787-96.
- 765 39. Peters SA, Huxley RR and Woodward M. Diabetes as risk factor for incident
- 766 coronary heart disease in women compared with men: a systematic review and

- meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary
- 768 events. *Diabetologia*. 2014;57:1542-51.
- 769 40. Gerdts E and Regitz-Zagrosek V. Sex differences in cardiometabolic disorders.
- 770 *Nat Med.* 2019;25:1657-1666.
- 771 41. Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A and
- Gourdy P. Sex differences in metabolic regulation and diabetes susceptibility.
- 773 *Diabetologia*. 2020;63:453-461.
- 42. Toedebusch R, Belenchia A and Pulakat L. Diabetic Cardiomyopathy: Impact
- of Biological Sex on Disease Development and Molecular Signatures. *Front Physiol.*
- 776 2018;9:453.
- 43. Murphy E, Amanakis G, Fillmore N, Parks RJ and Sun J. Sex Differences in
- 778 Metabolic Cardiomyopathy. *Cardiovasc Res.* 2017;113:370-377.
- 779 44. Vasques AC, Novaes FS, de Oliveira Mda S, Souza JR, Yamanaka A, Pareja JC,
- 780 Tambascia MA, Saad MJ and Geloneze B. TyG index performs better than HOMA
- 781 in a Brazilian population: a hyperglycemic clamp validated study. *Diabetes Res*
- 782 *Clin Pract*. 2011;93:e98-e100.
- 783 45. Toro-Huamanchumo CJ, Urrunaga-Pastor D, Guarnizo-Poma M, Lazaro-
- Alcantara H, Paico-Palacios S, Pantoja-Torres B, Ranilla-Seguin VDC and Benites-
- Zapata VA. Triglycerides and glucose index as an insulin resistance marker in a
- sample of healthy adults. *Diabetes Metab Syndr*. 2019;13:272-277.
- 787 46. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C and Zuñiga FA.
- 788 Association between insulin resistance and the development of cardiovascular

disease. *Cardiovasc Diabetol*. 2018;17:122.

47. Lakhani I, Leung KSK, Tse G and Lee APW. Novel Mechanisms in Heart Failure
With Preserved, Midrange, and Reduced Ejection Fraction. *Front Physiol*.

2019;10:874.

Table 1. The baseline characteristics of subjects in the Kailuan Cohort.

			Туб	G index	
	T 4 1	Q1	Q2	Q3	Q4
Characteristics	Total	3.60-8.18	8.18-8.57	8.57-9.05	9.05-12.51
Subjects (n)	95,996	23,997	24,000	24,001	23,998
TyG index	8.65±0.69	7.85±0.27	8.38±0.11	8.79±0.14	9.58±0.46
Age, years	51.4±12.5	50.2±13.7	51.4±12.7	52.1±12.2	52.0±11.4
Male, n (%)	76,364(79.6)	17,655(73.6)	18,994(79.1)	19,501(81.3)	20,214(84.2)
Height (cm)	167.4±7.0	166.7±7.0	167.5±7.0	167.6±7.0	167.9±6.9
BMI (kg/m ²)	25.0±3.5	23.4±3.2	24.6±3.3	25.6±3.3	26.4±3.4
Completed high school, n	18,746(19.5)	5673(23.6)	4483(18.7)	4448(18.5)	4142(17.3)
(%)					
Income≥800¥, n (%)	13,133(13.7)	3563(14.9)	3093(12.9)	3234(13.5)	3243(13.5)
Daily Smoker, n (%)	28,675(29.9)	6902(28.8)	6741(28.1)	7173(29.9)	7859(32.8)
Daily alcohol user, n (%)	16,725(17.4)	3891(16.2)	3834(16.0)	4125(17.2)	4875(20.3)
Activity physical activity,	13,935(14.5)	3654(15.2)	3356(14.0)	3535(14.7)	3390(14.1)
n (%)					
Systolic BP, mmHg	131±21	124±20	129±20	132±21	136±21
Diastolic BP, mmHg	83±12	80±11	83±11	85±1	87±12
FBG, mmol/L	5.47±1.67	4.80±0.68	5.09±0.76	5.44±1.11	6.54±2.66
TC, mg/dL	190.9±44.1	179.3±35.6	190.2±37.3	197.9±39.0	196.4±58.1

LDL-c, mg/dL	90.6±35.2	84.3±35.8	92.2±33.3	94.7±33.99	91.2±36.7
HDL-c, mg/dL	59.8±15.5	60.5±15.7	60.3±14.8	59.3±15.1	59.0±16.3
TG, mg/dL	112.4	62.0	97.4	137.2	245.1
ro, mg/dL	(78.8-170.8)	(51.3-72.6)	(86.7-108.0)	(120.4-158.4)	(192.9-346.0)
ha CDD maddl	0.80	0.60	0.72	0.88	1.02
hs-CRP, mg/dl	(0.30-2.16)	(0.21-1.84)	(0.29-1.99)	(0.33-2.16)	(0.40-2.61)
eGFR, mL/min/1.73m2	82.3±25.7	85.8±26.8	81.8±25.4	81.4±22.8	80.5±27.2
Diabetes Mellitus, n (%)	8408(8.8)	223(0.9)	542(2.3)	1699(7.1)	5944(24.8)
Hypertension, n (%)	4,1072(42.8)	6847(28.5)	9651(40.2)	11316(47.2)	13258(55.3)
Anti-hypertensive drugs,	9453(9.9)	1440(6.0)	1915(8.0)	2714(11.3)	3384(14.1)
n (%)					
Lipid-lowering drugs, n	709(0.7)	81(0.3)	130(0.5)	168(0.7)	330(1.4)
(%)					
Diabetes drugs, n (%)	2048(2.1)	121(0.5)	209(0.9)	442(1.8)	1273(5.3)

Abbreviations: BMI: body mass index; BP: blood pressure; FBG: fasting blood glucose;
TC: total cholesterol; LDL-c: low density lipoprotein cholesterol; HDL-c: low density
lipoprotein cholesterol; TG: triglyceride; eGFR: estimated glomerular filtration rate;

799 hs-CRP: high sensitivity C-reactive protein.

Table 2. The baseline characteristics of subjects in the cohort from Hong Kong.

			ТуС	G index	
	T 4.1	Q1	Q2	Q3	Q4
Characteristics	Total	4.78-6.89	6.90-7.31	7.32-7.80	7.81-11.38
Subjects (n)	19,345	4,861	4,859	4,812	4,813
TyG index	7.36±0.68	6.54±0.27	7.10±0.12	7.54±0.14	8.26±0.42
Age, years	60.1±12.9	58.1±13.9	60.6±12.9	60.6±12.3	61.3±12.2
Male, n (%)	7738 (40.0)	1780 (36.6)	1971 (40.6)	1935 (40.2)	2052 (42.6)
Systolic BP, mmHg	139±21	136±21	139±20	140±20	142±20
Diastolic BP, mmHg	76±11	75±12	76±11	77±11	77±11
FBG, mmol/L	6.79±3.18	5.35±0.97	5.96±1.41	6.72±2.19	9.16±4.94
TC, mg/dL	208.4±42.0	197.0±39.8	207.4±40.9	212.4±41.1	217.2±43.5
LDL-c, mg/dL	124.7±37.4	119.6±35.5	128.3±37.2	128.5±37.3	122.4±38.9
HDL-c, mg/dL	52.6±14.6	61.0±15.7	53.9±14.0	49.5±12.1	46.0±11.7
TC/4I	124.0	743.5	115.1	160.3	221.4
TG, mg/dL	(88.6-179.8)	(60.2-88.6)	(98.3-132.0)	(127.5-189.5)	(159.4-292.3)
Dyslipidemia, n (%)	9099 (47.0)	1930 (39.7)	2273 (46.8)	2446 (50.8)	2450 (50.9)
Diabetes Mellitus, n (%)	6524(33.7)	559 (11.5)	1138 (23.4)	1816 (37.7)	3011 (62.6)
Hypertension, n (%)	11,809 (61.0)	2591 (53.3)	2974 (61.2)	3037 (63.1)	3207 (66.6)
Chronic kidney disease, n	2930 (15.2)	543 (11.2)	730 (15.0)	744 (15.5)	913 (19.0)
(%)					

Anti-hypertensive drugs,	3834 (19.8)	755 (15.5)	990 (20.4)	1011 (21.0)	1078 (22.4)
n (%)					
Lipid-lowering drugs, n	1586 (8.2)	303 (6.2)	373 (7.7)	419 (8.7)	491 (10.2)
(%)					
Diabetes drugs, n (%)	995 (5.1)	110 (2.3)	194 (4.0)	246 (5.1)	445 (9.3)
Antiplatelets, n (%)	814 (4.2)	159 (3.3)	191 (3.9)	216 (4.5)	248 (5.2)

Table 3. Association between baseline TyG and incident heart failure in the Kailuan cohort.

	Q1	Q2	Q3	Q4	P for trend	Per unit increment	P value
Number of patients	23,997	24,000	24,001	23,998			
HF cases	497	576	729	924			
Persons	23997	24000	24001	23998			
Person-years	297098	295908	294857	292552			
HF incidence ¹	1.67(1.53-1.83)	1.95(1.79-2.11)	2.47(2.30-2.66)	3.16(2.96-3.37)			
Model 1 ²	1	1.16(1.03-1.31)	1.48(1.32-1.66)	1.90(1.70-2.11)	< 0.001	1.44(1.37-1.51)	< 0.001
Model 2 ³	1	1.12(1.00-1.27)	1.41(1.26-1.58)	1.90(1.70-2.12)	< 0.001	1.47(1.40-1.55)	< 0.001
Model 3 ⁴	1	1.00(0.88-1.12)	1.12(1.00-1.26)	1.23(1.09-1.39)	< 0.001	1.17(1.10-1.24)	< 0.001
Sensitivity analysis							
Sensitivity analysis 1 ⁵	1	1.00(0.88-1.13)	1.14(1.01-1.28)	1.23(1.10-1.41)	<0.001	1.18(1.10-1.25)	<0.001

Sensitivity analysis 2 ⁶	1	0.97(0.84-1.11)	1.11(0.98-1.27)	1.17(1.02-1.34)	0.006	1.13(1.06-1.22)	< 0.001
Competing risk regression ⁷	1	1.01(0.90-1.14)	1.14(1.02-1.29)	1.25(1.10-1.41)	< 0.001	1.18(1.10-1.25)	< 0.001

¹HF incidence; The incidence rates per 1000 person years with the corresponding 95% confidence intervals are shown

²Model 1: Unadjusted. The hazard ratios with the corresponding 95% confidence intervals are shown.

³ Model 2: Age-sex adjusted. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁴ Model 3: Adjusted for age, gender, education, income, physical activity, smoking status, alcohol intake, diabetes, LDL-c, HDL-c, SBP, DBP, BMI, eGFR, hs-CRP, anti-hypertensive drugs, anti-diabetes drugs, and lipid-lowering drugs. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁵ Sensitivity analysis 1: exclude follow-up time less than 2 years, remained 95,275 subjects with 2,497 HF cases. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁶ Sensitivity analysis 2: exclude subjects with medication at baseline (anti-hypertension drugs, lipid lower drugs, anti-diabetes drugs), remained 85,118 subjects with 2,118 HF cases. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁷ Competing risk regression: sub-hazard ratios with the corresponding 95% confidence intervals are shown.

Table 4. Association between baseline TyG index and incident heart failure in the cohort from Hong Kong.

	Q1	Q2	Q3	Q4	P for trend	Per unit increment	P value
Number of patients	4,861	4,859	4,812	4,813			
HF cases	342	404	454	509			
Persons	4861	4859	4812	4813			
Person-years	79,353	77,644	77,335	75,360			
HF incidence ¹	4.31(3.88-4.79)	5.20(4.72-5.74)	5.87(5.34-6.42)	6.75(6.19-7.37)			
Model 1 ²	1	1.21(1.05-1.40)	1.36(1.19-1.57)	1.58(1.38-1.82)	< 0.001	1.30(1.22-1.39)	< 0.001
Model 2 ³	1	1.09(0.94-1.26)	1.23(1.07-1.42)	1.39(1.21-1.59)	< 0.001	1.23(1.14-1.31)	< 0.001
Model 3 ⁴	1	1.07(0.92-1.23)	1.17(1.01-1.35)	1.21(1.04-1.40)	0.007	1.13(1.05-1.22)	0.001
Sensitivity analysis							
Sensitivity analysis 1 ⁵	1	1.07(0.92-1.23)	1.17(1.01-1.35)	1.22(1.05-1.41)	0.005	1.14(1.05-1.23)	0.001

Sensitivity analysis 2 ⁶	1	1.16(0.98-1.37)	1.22(1.03-1.45)	1.29(1.08-1.53)	0.005	1.16(1.06-1.27)	0.001
Competing risk regression ⁷	1	1.06(0.91-1.22)	1.21(1.04-1.40)	1.24(1.07-1.44)	0.001	1.15(1.06-1.24)	< 0.001

¹HF incidence; The incidence rates per 1000 person years with the corresponding 95% confidence intervals are shown

² Model 1: Unadjusted. The hazard ratios with the corresponding 95% confidence intervals are shown.

³ Model 2: Age-sex adjusted. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁴ Model 3: Adjusted for age, sex, hypertension, diabetes mellitus, chronic kidney disease, dyslipidemia, antihypertensives, anti-diabetic drugs, antiplatelets, lipid-lowering drugs. The hazard ratios with the corresponding 95% confidence intervals are shown.


⁵ Sensitivity 1: exclude follow-up time less than 2 years, remained 19,227 subjects with 1,709 HF cases. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁶ Sensitivity 2: exclude those with medications at baseline, remained 14,842 subjects with 1,223 HF cases. The hazard ratios with the corresponding 95% confidence intervals are shown.

⁷Competing risk regression: sub-hazard ratios with the corresponding 95% confidence intervals are shown.

Figure legends.

Figure 1. Kaplan-Meier curve of the cumulative incidence of incident heart failure for the (A) Kailuan cohort and (B) Hong Kong cohort, stratifying by quartiles of the triglyceride-glucose index.






Figure 2. Subgroup analysis of the association between TyG index and incident HF for the (A) Kailuan cohort and (B) Hong Kong cohort. HR: hazard ratio; CI: confidence interval.

Subgoups	Case/Total	HR (95% CI)	P value		P for interaction
Age, years				1	
< 65	1662/82362	1.15 (1.06-1.24)	< 0.001		0.08
≥ 65	1064/13634	1.16 (1.05-1.29)	0.004		
Gender					
Male	2322/76364	1.15 (1.08-1.23)	< 0.001		0.02
Female	404/19632	1.21 (1.02-1.42)	0.027		
BMI, kg/m ²				_	
< 25	1145/50179	1.15 (1.05-1.27)	0.004		0.46
≥ 25	1581/45817	1.17 (1.08-1.26)	< 0.001		0.40
Diabetes Mellitus	1301/43017	1.17 (1.00-1.20)	10.001	_	
Yes	541/8408	1.26 (1.12-1.42)	< 0.001		0.13
No	2185/87588	1.13 (1.05-1.21)	0.001		0.13
Hypertension	2103/0/300	1.13 (1.03-1.21)	0.001		
Yes	1750/41070	1.17 (1.00 1.20)	<0.001		0.52
	1758/41072	1.17 (1.08-1.26)	< 0.001		0.53
No	968/54924	1.21 (1.01-1.24)	0.029		
Dylslipidemia					
Yes	1077/30732	1.10 (1.00-1.21)	0.05	-	0.08
No	1649/65264	1.10 (0.98-1.23)	0.10	 	
hs-CRP mg/dL					
< 1	1207/54207	1.16 (1.06-1.28)	0.001		0.25
≥ 1	1519/41789	1.16 (1.07-1.26)	< 0.001		
			—		
			0.8	1.0 1.6	
(B)					
` ′					
(B) Subgoups	Case/Total	HR (95% CI)	P value		P for interaction
Subgoups Age, years		, ,			
Subgoups	Case/Total 567/11607	1.14 (0.98-1.33)	P value	<u> </u>	P for interactio
Subgoups Age, years		, ,		<u> </u>	
Subgoups Age, years < 65 ≥ 65	567/11607	1.14 (0.98-1.33)	0.06	-	0.47
Subgoups Age, years < 65 ≥ 65	567/11607	1.14 (0.98-1.33)	0.06		
Subgoups Age, years < 65 ≥ 65 Gender	567/11607 1142/7738	1.14 (0.98-1.33) 1.13 (1.03-1.24)	0.06 0.01	+	0.47
Subgoups Age, years < 65 ≥ 65 Gender Male	567/11607 1142/7738 763/7738	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17)	0.06 0.01 0.34	-	0.47
Subgoups Age, years < 65 \$\geq 65\$ Gender Male Female	567/11607 1142/7738 763/7738	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17)	0.06 0.01 0.34		0.47
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus	567/11607 1142/7738 763/7738 946/11607 719/6524	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35)	0.06 0.01 0.34 <0.001	+	0.47 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No	567/11607 1142/7738 763/7738 946/11607	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64)	0.06 0.01 0.34 <0.001	+	0.47 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Hypertension	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18)	0.06 0.01 0.34 <0.001 0.001 0.21		0.47 0.11 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Ney Yes Yes	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821 1199/11809	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18) 1.13 (1.02-1.24)	0.06 0.01 0.34 <0.001 0.001 0.21		0.47 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Hypertension Yes No	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18)	0.06 0.01 0.34 <0.001 0.001 0.21		0.47 0.11 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Hypertension Yes No Dylslipidemia	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821 1199/11809 510/7536	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18) 1.13 (1.02-1.24) 1.12 (0.96-1.31)	0.06 0.01 0.34 <0.001 0.001 0.21 0.01 0.04		0.47 0.11 0.11 0.81
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Hypertension Yes No Dylslipidemia Yes	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821 1199/11809 510/7536 625/9099	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18) 1.13 (1.02-1.24) 1.12 (0.96-1.31) 1.17 (1.01-1.34)	0.06 0.01 0.34 <0.001 0.001 0.21 0.01 0.04		0.47 0.11 0.11
Subgoups Age, years < 65 ≥ 65 Gender Male Female Diabetes Mellitus Yes No Hypertension Yes No Dylslipidemia	567/11607 1142/7738 763/7738 946/11607 719/6524 990/12821 1199/11809 510/7536	1.14 (0.98-1.33) 1.13 (1.03-1.24) 1.05 (0.94-1.17) 1.22 (1.10-1.64) 1.21 (1.07-1.35) 1.05 (0.93-1.18) 1.13 (1.02-1.24) 1.12 (0.96-1.31)	0.06 0.01 0.34 <0.001 0.001 0.21 0.01 0.04		0.47 0.11 0.11 0.81

Figure 3. Forest plots for the meta-analysis of the association between TyG index with HF risk. (A) TyG index analyzed as a categorical variable.

(B) TyG index analyzed as a continuous variable.

A)				Hazard Ratio		Hazard	l Ratio		
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI		IV, Rando	m, 95% C	1	
Hong Kong	0.1906	0.0772	39.0%	1.21 [1.04, 1.41]				—	-
Kailuan	0.207	0.0617	61.0%	1.23 [1.09, 1.39]			-		
Total (95% CI)			100.0%	1.22 [1.11, 1.34]			⋖		
Heterogeneity: Tau ² =	0.00; Chi ² = 0.03, df =	= 1 (P = 0).87); I ² = (0%	0.7	 	1.:		1.5
Test for overall effect:	Z = 4.16 (P < 0.0001))			Lowest guarti		Highest o		

(B)					Hazard Ratio		Haz	ard Ratio	o		
_	Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI		IV, Rar	<u>ndom, 95</u>	% CI		
	Hong Kong	0.1222	0.0375	41.4%	1.13 [1.05, 1.22]			-	_		
	Kailuan	0.157	0.0315	58.6%	1.17 [1.10, 1.24]			-	•		
	Total (95% CI)			100.0%	1.15 [1.10, 1.21]			- -	•		
	Heterogeneity: Tau ² = Test for overall effect:		0%	0.7 Lo	0.85 w level of Ty	1 /G High	1.2 level of	1. TyG	.5		

Figure 4. Mendelian randomization (MR) association between genetically determined TyG index and HF. Sensitivity analysis 1: multivariable MR through IVW method after adjusting for cofounders including BMI, SBP, DBP, LDL-c, and HDL-c. Sensitivity analysis 2: MR analysis through IVW after excluding any SNPs significantly associated with those confounders, including BMI, SBP, DBP, LDL-c, and HDL-c. SNPs: single-nucleotide polymorphisms; OR: odds ratio; IVW: inverse-variance weighted.

Methods	SNPs				OR (95% CI)	P value
Main analysis						
IVW	183				1.27 (1.15-1.40)	< 0.001
Weighted Median	183				1.37 (1.19-1.58)	< 0.001
MR Egger	183			-	1.29 (1.10-1.51)	< 0.001
MR PRESSO	181				1.31 (1.19-1.45)	< 0.001
Sensitvity analysis 1						
IVW	183				1.20 (1.02-1.41)	0.03
Sensitvity analysis 2	2					
IVW	151				1.19 (1.05-1.35)	0.01
					•	
		0.8	.0	1.6		